63744-41-2

Usage

Uses

Used in Pharmaceutical Industry:
5-Chloroimidazo[1,2-a]pyrazine is used as a chemical intermediate for the synthesis of various pharmaceuticals and agrochemicals, contributing to the development of new drugs.
Used in Organic Compounds Production:
5-Chloroimidazo[1,2-a]pyrazine is utilized as a building block in the production of a range of organic compounds, showcasing its versatility in chemical synthesis.
Used in Anti-inflammatory Applications:
5-Chloroimidazo[1,2-a]pyrazine is being studied for its potential as an anti-inflammatory agent, which could be beneficial in the treatment of various inflammatory conditions.
Used in Anti-cancer Applications:
It is also being researched for its potential as an anti-cancer agent, indicating its possible role in the development of new cancer therapies.
While the exact properties and potential applications of 5-Chloroimidazo[1,2-a]pyrazine are still under investigation, its current uses and ongoing research highlight its importance in the fields of pharmaceuticals and organic chemistry.

InChI:InChI=1/C6H4ClN3/c7-5-3-8-4-6-9-1-2-10(5)6/h1-4H

Upstream product

• 7252-83-7 1-bromo-2,2-dimethoxyethane 
• 33332-28-4 2-amino-6-chloropyrazine 
• 107-20-0 2-chloroethanal 

Relevant academic research and scientific papers

BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS

Described herein are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R 4, Y1, Y2, n and p are as defined herein.

SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS

Disclosed are sulfonamide compounds of Formula (I): or stereoisomers, N-oxides, prodrugs, or pharmaceutically acceptable salts thereof, wherein ring A, R1, R2, R3, R4 and R5 are defined herein. Also disclosed are methods of using such compounds in the treatment of conditions related to CYP17 enzyme, such as cancer, and pharmaceutical compositions comprising such compounds.

Inhibitors of CYP 17

The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R53, R54, p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C17,20-lyase inhibitors.

1, 3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF CYP 17

The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R53, R54, p, q and n are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C17,20-lyase inhibitors.